ES2385450T3 - Células madre mesenquimatosas y sus utilizaciones - Google Patents
Células madre mesenquimatosas y sus utilizaciones Download PDFInfo
- Publication number
- ES2385450T3 ES2385450T3 ES05725577T ES05725577T ES2385450T3 ES 2385450 T3 ES2385450 T3 ES 2385450T3 ES 05725577 T ES05725577 T ES 05725577T ES 05725577 T ES05725577 T ES 05725577T ES 2385450 T3 ES2385450 T3 ES 2385450T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- mscs
- mesenchymal stem
- stem cells
- lymphocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 171
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 241001465754 Metazoa Species 0.000 claims abstract description 10
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 7
- 230000001363 autoimmune Effects 0.000 claims abstract description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 6
- 201000002491 encephalomyelitis Diseases 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 64
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 54
- 210000004698 lymphocyte Anatomy 0.000 description 26
- 230000028327 secretion Effects 0.000 description 26
- 210000001744 T-lymphocyte Anatomy 0.000 description 23
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 23
- 229960002986 dinoprostone Drugs 0.000 description 22
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 22
- 230000001965 increasing effect Effects 0.000 description 17
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 16
- 108010047620 Phytohemagglutinins Proteins 0.000 description 12
- 210000000822 natural killer cell Anatomy 0.000 description 12
- 230000001885 phytohemagglutinin Effects 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 10
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 10
- 239000012228 culture supernatant Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 102000003814 Interleukin-10 Human genes 0.000 description 9
- 108090000174 Interleukin-10 Proteins 0.000 description 9
- 102000004388 Interleukin-4 Human genes 0.000 description 9
- 108090000978 Interleukin-4 Proteins 0.000 description 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 9
- 229940076144 interleukin-10 Drugs 0.000 description 9
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 8
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 8
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 8
- 230000001464 adherent effect Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 229960000905 indomethacin Drugs 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102100040247 Tumor necrosis factor Human genes 0.000 description 7
- 230000000735 allogeneic effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 6
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 6
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 6
- 210000003162 effector t lymphocyte Anatomy 0.000 description 6
- 102000046949 human MSC Human genes 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000003289 regulatory T cell Anatomy 0.000 description 5
- 102000006354 HLA-DR Antigens Human genes 0.000 description 4
- 108010058597 HLA-DR Antigens Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 230000001745 anti-biotin effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960001388 interferon-beta Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000031873 Animal Disease Models Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101150101999 IL6 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000011558 animal model by disease Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 210000003035 hyaline cartilage Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55511804P | 2004-03-22 | 2004-03-22 | |
| US555118P | 2004-03-22 | ||
| PCT/US2005/008506 WO2005093044A1 (en) | 2004-03-22 | 2005-03-15 | Mesenchymal stem cells and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2385450T3 true ES2385450T3 (es) | 2012-07-25 |
Family
ID=46060822
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05725577T Expired - Lifetime ES2385450T3 (es) | 2004-03-22 | 2005-03-15 | Células madre mesenquimatosas y sus utilizaciones |
| ES10011224.2T Expired - Lifetime ES2643076T3 (es) | 2004-03-22 | 2005-03-15 | Células madre mesenquimales y sus usos |
| ES14172807T Expired - Lifetime ES2657382T5 (es) | 2004-03-22 | 2005-03-15 | Células madre mesenquimales y usos de las mismas |
| ES10011226.7T Expired - Lifetime ES2645018T3 (es) | 2004-03-22 | 2005-03-15 | Células madre mesenquimales y usos para estas |
| ES10011225.9T Expired - Lifetime ES2544689T3 (es) | 2004-03-22 | 2005-03-15 | Células madre mesenquimales y usos de las mismas |
| ES14172800T Expired - Lifetime ES2708627T3 (es) | 2004-03-22 | 2005-03-15 | Células madre mesenquimales y sus usos |
| ES10011223.4T Expired - Lifetime ES2643030T3 (es) | 2004-03-22 | 2005-03-15 | Células madre mesenquimales y sus usos |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10011224.2T Expired - Lifetime ES2643076T3 (es) | 2004-03-22 | 2005-03-15 | Células madre mesenquimales y sus usos |
| ES14172807T Expired - Lifetime ES2657382T5 (es) | 2004-03-22 | 2005-03-15 | Células madre mesenquimales y usos de las mismas |
| ES10011226.7T Expired - Lifetime ES2645018T3 (es) | 2004-03-22 | 2005-03-15 | Células madre mesenquimales y usos para estas |
| ES10011225.9T Expired - Lifetime ES2544689T3 (es) | 2004-03-22 | 2005-03-15 | Células madre mesenquimales y usos de las mismas |
| ES14172800T Expired - Lifetime ES2708627T3 (es) | 2004-03-22 | 2005-03-15 | Células madre mesenquimales y sus usos |
| ES10011223.4T Expired - Lifetime ES2643030T3 (es) | 2004-03-22 | 2005-03-15 | Células madre mesenquimales y sus usos |
Country Status (5)
| Country | Link |
|---|---|
| JP (8) | JP6114500B2 (enExample) |
| AT (1) | ATE556134T1 (enExample) |
| CA (3) | CA2868733C (enExample) |
| ES (7) | ES2385450T3 (enExample) |
| TR (1) | TR201901268T4 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3461884B1 (en) * | 2004-03-22 | 2025-05-28 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
| US12473547B2 (en) | 2017-11-22 | 2025-11-18 | Mesoblast International Sàrl | Use of mesenchymal lineage precursor cells or stem cells (MLPSCs) for delivery of oligonucleotides in the treatment of cancer |
| US12697355B2 (en) | 2020-03-05 | 2026-08-04 | Mesoblast International Sárl | Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells |
| US12702683B2 (en) | 2019-01-03 | 2026-08-11 | Mesoblast International Sárl | Method for improving visual acuity |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2385450T3 (es) * | 2004-03-22 | 2012-07-25 | Osiris Therapeutics, Inc. | Células madre mesenquimatosas y sus utilizaciones |
| US20150110751A1 (en) * | 2012-05-16 | 2015-04-23 | Kennedy Krieger Institute, Inc. | Stem cells as an individualized maternal therapy for prevention of prematurity |
| JP2016210730A (ja) * | 2015-05-08 | 2016-12-15 | 上田 実 | 医薬組成物及びその製造方法並びに医薬品 |
| EP3543331A4 (en) | 2016-11-15 | 2020-07-01 | Kaneka Corporation | CELL POPULATION CONTAINING MESENCHYMAL STEM CELLS DERIVED FROM F RATE APPENDICES, METHOD FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION |
| JP7454379B2 (ja) | 2017-12-28 | 2024-03-22 | 株式会社カネカ | 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物 |
| WO2020251020A1 (ja) | 2019-06-14 | 2020-12-17 | 株式会社カネカ | 間葉系細胞を含む細胞集団、それを含む医薬組成物、及び、その製造方法 |
| WO2021028583A1 (en) * | 2019-08-15 | 2021-02-18 | Nextcell Pharma Ab | Allogeneic composition for treatment of cns disorders |
| CN113813288B (zh) * | 2021-08-11 | 2024-02-13 | 谢岩 | 间充质干细胞及包含其的组合物用于制备治疗烧伤难愈创面的药物的用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0651641B2 (ja) * | 1983-08-29 | 1994-07-06 | 株式会社ミドリ十字 | ガンマ・インターフェロン組成物 |
| WO1987005518A1 (en) * | 1986-03-17 | 1987-09-24 | Schering Corporation | Treatment of cancers with gamma interferon |
| CA2191733A1 (en) * | 1994-06-07 | 1995-12-21 | Daniel A. Vallera | Methods for inhibiting antigen specific t cell responses |
| JP2000508922A (ja) * | 1996-04-26 | 2000-07-18 | ケース ウエスターン リザーブ ユニバーシティ | 間葉幹細胞を用いる皮膚再生 |
| WO1999047163A2 (en) * | 1998-03-18 | 1999-09-23 | Osiris Therapeutics, Inc. | Mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| US6368636B1 (en) * | 1998-03-18 | 2002-04-09 | Osiris Therapeutics, Inc. | Mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| JP2002510655A (ja) * | 1998-04-03 | 2002-04-09 | オシリス セラピューティクス，インコーポレイテッド | 免疫抑制剤としての間葉幹細胞によるｔ細胞応答を阻害する方法とその利用 |
| AU2925401A (en) * | 2000-01-19 | 2001-07-31 | Parkash S Gill | Methods and compositions for antisense vegf oligonucleotides |
| WO2001080865A2 (en) * | 2000-04-25 | 2001-11-01 | Osiris Therapeutics, Inc. | Joint repair using mesenchymal stem cells |
| MXPA04007426A (es) * | 2002-02-01 | 2004-10-11 | Schering Corp | Usos de citosina de mamifero; reactivos relacionados. |
| JP3897343B2 (ja) * | 2002-08-01 | 2007-03-22 | 株式会社林原生物化学研究所 | 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質 |
| US20040258670A1 (en) * | 2002-12-05 | 2004-12-23 | Case Western Reserve University | Cell-based therapies for ischemia |
| CA2564679C (en) * | 2004-03-22 | 2015-06-23 | Osiris Therapeutics, Inc. | Mesenchymal stem cells and uses therefor |
| ES2385450T3 (es) * | 2004-03-22 | 2012-07-25 | Osiris Therapeutics, Inc. | Células madre mesenquimatosas y sus utilizaciones |
-
2005
- 2005-03-15 ES ES05725577T patent/ES2385450T3/es not_active Expired - Lifetime
- 2005-03-15 ES ES10011224.2T patent/ES2643076T3/es not_active Expired - Lifetime
- 2005-03-15 CA CA2868733A patent/CA2868733C/en not_active Expired - Lifetime
- 2005-03-15 ES ES14172807T patent/ES2657382T5/es not_active Expired - Lifetime
- 2005-03-15 CA CA3135582A patent/CA3135582A1/en active Pending
- 2005-03-15 TR TR2019/01268T patent/TR201901268T4/tr unknown
- 2005-03-15 CA CA2934682A patent/CA2934682C/en not_active Expired - Lifetime
- 2005-03-15 ES ES10011226.7T patent/ES2645018T3/es not_active Expired - Lifetime
- 2005-03-15 ES ES10011225.9T patent/ES2544689T3/es not_active Expired - Lifetime
- 2005-03-15 AT AT05725577T patent/ATE556134T1/de active
- 2005-03-15 ES ES14172800T patent/ES2708627T3/es not_active Expired - Lifetime
- 2005-03-15 ES ES10011223.4T patent/ES2643030T3/es not_active Expired - Lifetime
-
2012
- 2012-03-15 JP JP2012058539A patent/JP6114500B2/ja not_active Expired - Lifetime
-
2014
- 2014-11-28 JP JP2014241859A patent/JP5997237B2/ja not_active Expired - Lifetime
-
2017
- 2017-01-13 JP JP2017003854A patent/JP6382360B2/ja not_active Expired - Lifetime
- 2017-08-10 JP JP2017155229A patent/JP6757300B2/ja not_active Expired - Lifetime
-
2018
- 2018-10-09 JP JP2018190636A patent/JP6757383B2/ja not_active Expired - Lifetime
-
2020
- 2020-03-18 JP JP2020047240A patent/JP7033159B2/ja not_active Expired - Lifetime
-
2021
- 2021-08-30 JP JP2021140167A patent/JP7546239B2/ja not_active Expired - Lifetime
-
2023
- 2023-02-20 JP JP2023023996A patent/JP2023065486A/ja active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3461884B1 (en) * | 2004-03-22 | 2025-05-28 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
| US12473547B2 (en) | 2017-11-22 | 2025-11-18 | Mesoblast International Sàrl | Use of mesenchymal lineage precursor cells or stem cells (MLPSCs) for delivery of oligonucleotides in the treatment of cancer |
| US12702683B2 (en) | 2019-01-03 | 2026-08-11 | Mesoblast International Sárl | Method for improving visual acuity |
| US12697355B2 (en) | 2020-03-05 | 2026-08-04 | Mesoblast International Sárl | Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018009002A (ja) | 2018-01-18 |
| JP6757300B2 (ja) | 2020-09-16 |
| JP2012176948A (ja) | 2012-09-13 |
| JP2021191771A (ja) | 2021-12-16 |
| JP2020111591A (ja) | 2020-07-27 |
| JP6114500B2 (ja) | 2017-04-12 |
| ES2544689T3 (es) | 2015-09-02 |
| ES2645018T3 (es) | 2017-12-01 |
| HK1205677A1 (en) | 2015-12-24 |
| ATE556134T1 (de) | 2012-05-15 |
| JP2019014747A (ja) | 2019-01-31 |
| JP6757383B2 (ja) | 2020-09-16 |
| JP7546239B2 (ja) | 2024-09-06 |
| ES2643076T3 (es) | 2017-11-21 |
| CA2868733A1 (en) | 2005-10-06 |
| JP6382360B2 (ja) | 2018-08-29 |
| CA2868733C (en) | 2019-12-17 |
| CA2934682A1 (en) | 2005-10-06 |
| JP5997237B2 (ja) | 2016-09-28 |
| ES2657382T3 (es) | 2018-03-05 |
| JP2017080507A (ja) | 2017-05-18 |
| ES2708627T3 (es) | 2019-04-10 |
| HK1205531A1 (en) | 2015-12-18 |
| CA3135582A1 (en) | 2005-10-06 |
| TR201901268T4 (tr) | 2019-02-21 |
| CA2934682C (en) | 2021-12-07 |
| JP7033159B2 (ja) | 2022-03-09 |
| ES2643030T3 (es) | 2017-11-21 |
| JP2015061862A (ja) | 2015-04-02 |
| JP2023065486A (ja) | 2023-05-12 |
| ES2657382T5 (es) | 2021-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1727892B1 (en) | Mesenchymal stem cells and uses therefor | |
| ES2765650T3 (es) | Células madre mesenquimales para su uso en el mejoramiento de la función pulmonar | |
| JP7033159B2 (ja) | 間葉幹細胞及びその使用法 | |
| AU2012205269B2 (en) | Mesenchymal stem cells and uses therefor | |
| KR101577553B1 (ko) | 중간엽 줄기 세포 및 그에 대한 용도 | |
| ES2577703T3 (es) | Células madre mesenquimales para su uso en el tratamiento de una enfermedad pulmonar | |
| AU2017268656B2 (en) | Mesenchymal stem cells and uses therefor | |
| HK1262056A1 (en) | Mesenchymal stem cells and uses therefor | |
| HK1205531B (en) | Mesenchymal stem cells and uses therefor |